Open AccessPan‑RAF inhibitor LY3009120 is highly synergistic with low‑dose cytarabine, but not azacitidine, in acute myeloid leukemia with RAS mutations
Author(s) -
Jihyun Park,
Hyejoo Park,
Ja Min Byun,
Junshik Hong,
Dong Yeop Shin,
Youngil Koh,
Sung Soo Yoon
Publication year - 2021
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2021.13006
Subject(s) - cytarabine , myeloid leukemia , cancer research , azacitidine , kras , neuroblastoma ras viral oncogene homolog , cell cycle , myeloid , leukemia , apoptosis , oncogene , mapk/erk pathway , medicine , biology , cancer , immunology , kinase , colorectal cancer , biochemistry , gene expression , dna methylation , gene , microbiology and biotechnology